ABSTRACT
INTRODUCTION
Hypertensive disorders of pregnancy include gestational hypertension (GH), chronic hypertension and pre-eclampsia (PE). They complicate up to 10% of pregnancies and are associated with adverse maternal and fetal outcomes, such as eclampsia, stroke, renal and hepatic dysfunction, fetal growth restriction and stillbirth [1] [2] [3] . Monitoring, early recognition and treatment are therefore key to reducing severe complications and mortality 4 . Traditionally, women who develop hypertension in pregnancy are advised to attend an outpatient service or day assessment unit (DAU) at their maternity hospital, commonly two to three times a week, for blood pressure monitoring and urine testing 5 . The purpose of these assessments is to monitor for the development of PE and/or placental insufficiency. However, the vast majority (more than 80%) of these women do not develop PE 6 . Frequent monitoring can be a source of anxiety for these women and their families, is demanding for patients in terms of time, transport costs and work absence, and has significant service implications for healthcare providers.
These women may also undergo unnecessary medical intervention, such as early delivery.
An alternative to this pathway is home blood-pressure monitoring (HBPM), in which patients monitor and record their own blood pressure using a validated machine, with instructions from a healthcare professional on the frequency of monitoring and when to attend the hospital. HBPM is recommended in the general population for diagnosing hypertension, but there is a paucity of data on the use of HBPM in pregnancy [7] [8] [9] . It has also been noted that 30% of pregnant women monitor their own blood pressure without informing their healthcare provider and using a wide range of devices, not all of which have been validated in pregnancy 10, 11 . This highlights the need for evidence-based patient education to establish and maintain safety of this practice. We therefore developed a pathway for HBPM in pregnancy, in which eligible women performed the majority of blood pressure checks at home and recorded the results in their notes or on a smartphone application. Our main aim was to assess if HBPM can be used in women at risk of PE and whether such monitoring reduces the number of visits to antenatal services without causing any discernible adverse outcome.
METHODS

Population and study design
This was a case-control study at St George's Hospital, University of London, of a cohort of hypertensive pregnant women enrolled on a HBPM pathway and a control group managed according to the traditional pathway of regular DAU visits for blood-pressure monitoring. Inclusion criteria were chronic hypertension, GH or high risk of developing PE, no significant proteinuria (≤ 1+ proteinuria on dipstick testing), and normal biochemical and hematological markers. Pregnant women in the HBPM group presented via referral either to the hypertension clinic or to the DAU between December 2013 and November 2016. HBPM was implemented as a quality improvement initiative at St George's Hospital. The control group was derived retrospectively from maternity databases and consisted of a historic cohort of women who presented to the DAU with hypertension in pregnancy and were managed as per the local hospital protocol prior to the implementation of HBPM. Search criteria included women referred to the DAU for blood-pressure monitoring who did not have a plan for delivery made within 1 week of their first visit. Exclusion criteria were maternal age < 16 years, systolic blood pressure > 155 mmHg or diastolic blood pressure > 100 mmHg, significant proteinuria (≥ 2+ proteinuria on dipstick testing or protein/creatinine ratio > 30 mg/mmol), evidence of small-for-gestational age (estimated fetal weight < 10 th centile), signs of severe PE (oliguria of < 500 mL urine output in 24 h, cerebral or visual disturbance, pulmonary edema, epigastric or right upper-quadrant pain, impaired liver function (twice the upper limit of normal levels for aspartate transaminase and/or alanine transaminase), thrombocytopenia (platelet count < 100 000/mm 3 )), significant mental health concerns or insufficient understanding of the English language.
Diagnoses of GH and PE were made according to the criteria of the International Society for the Study of Hypertension in Pregnancy 12 . GH was diagnosed in the presence of systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg on at least two occasions 4 h apart, developing after 20 weeks of gestation in a previously normotensive woman, in the absence of significant proteinuria. PE was diagnosed in the presence of GH with proteinuria ≥ 300 mg in 24 h, or two readings of ≥ 2+ on dipstick analysis of midstream or catheter urine specimens if no 24-h collection was available. PE superimposed on chronic hypertension was diagnosed in the presence of significant proteinuria (as defined above) after 20 weeks of gestation in women with known chronic hypertension (history of hypertension before conception or presence of hypertension at booking visit before 20 weeks of gestation, in the absence of trophoblastic disease). Diagnosis of chronic hypertension was made when there was a documented presence of chronic non-gestational hypertension prior to the current pregnancy or history of antihypertensive medication prior to 20 + 0 weeks' gestation. White-coat hypertension was diagnosed when there were confirmed high blood-pressure recordings in the hospital/clinic with normal readings on HBPM or ambulatory monitoring. Ethical approval was obtained for the study (16/NW/0206).
Home blood-pressure monitoring pathway
Eligible patients were counseled and trained by a specialist midwife and provided with an automated Microlife© 'WatchBP Home' blood-pressure machine (Microlife Corporation, Taipei, Taiwan), which has been validated for use in pregnancy and PE 13 . They were taught how to measure their blood pressure accurately and record readings in their notes or on a specially designed smartphone app (Hampton Medical, Trakka Medical, UK). Each patient was given a personalized schedule of frequency of monitoring and timing of hospital visits (to either DAU or antenatal clinic), depending on their clinical need. While the schedule varied per patient, the frequency of monitoring complied with National Institute for Health and Care Excellence (NICE) guidelines on hypertension in pregnancy 5 . A typical regime for a woman with well-controlled chronic hypertension would be to measure blood pressure two or three times a week, whereas a woman initiating new treatment would be asked to measure blood pressure twice a day and would be reviewed 1 week later. The same specialist midwife reviewed patients at interim visits and HBPM recordings were reviewed. Blood pressure and urine were assessed and ultrasound examination for fetal wellbeing was performed as indicated. Patients were given written instructions regarding when to present to hospital based on their HBPM readings being out of normal range or on their reporting symptoms of PE. Our protocol used a systolic blood pressure of > 155 mmHg or a diastolic blood pressure of > 100 mmHg as the trigger for a patient to contact the hospital for review, to avoid patients developing severe hypertension at home. This is in line with NICE recommendations for hospital admission for systolic blood pressure of 160 mmHg or diastolic blood pressure of 110 mmHg 5 . For those using the smartphone app, a warning was generated automatically if they inputted an abnormal reading. Any patient presenting with such a concern was reviewed as per normal hospital protocol.
Patients in the control group either presented directly to the DAU or were referred from an antenatal clinic. They were managed according to the hospital protocol and had all blood-pressure checks performed in the DAU. The hospital protocol at that time was based on NICE guidelines for hypertension in pregnancy and follow-up visits were once or twice a week, depending on severity of hypertension 5 .
Data on maternal age, body mass index (BMI) at booking, ethnicity, parity, smoking status, mode of conception and pregnancy outcome were collected. The diagnoses at the start of blood pressure monitoring and at delivery were ascertained from medical records. We also recorded the duration of blood pressure monitoring, number of blood pressure-related visits to the DAU, hypertension clinic and family practitioner, number of ultrasound scans, hematological and biochemistry tests on maternal blood, administration of steroids and magnesium sulfate, and number of blood-pressure-related hospital admissions or admission to the high-dependency unit (HDU) for severe PE.
Adverse pregnancy outcome
Maternity, ultrasound and neonatal records were reviewed to collect data on adverse maternal, fetal and neonatal outcomes. Adverse maternal outcome included acute renal failure (maternal serum creatinine level > 100 μmol/L antenatally or >130 μmol/L postnatally) or need for dialysis, acute myocardial ischemia, need for third intravenous agent to control blood pressure (i.e. in addition to labetalol and hydralazine), hypertensive encephalopathy (altered mental status with characteristic cerebral imaging), cortical blindness, retinal detachment, stroke (ischemic or hemorrhagic), pulmonary edema or adult respiratory distress syndrome (defined by characteristic pulmonary imaging in addition to oxygen requirement), need for mechanical ventilatory support (other than for Cesarean section), disseminated intravascular coagulation, thrombotic thrombocytopenic purpura or hemolytic uremic syndrome, acute fatty liver, liver hematoma or rupture, placental abruption, and maternal death. Adverse fetal outcome included preterm delivery (< 37 + 0 weeks' gestation), small-for-gestational age (birth weight < 10 th centile), fetal growth restriction (birth weight < 5 th centile) and antepartum or intrapartum fetal death. Adverse neonatal outcome included neonatal death, respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, bronchopulmonary dysplasia, periventricular leukomalacia, retinopathy of prematurity, seizure and admission to the neonatal unit for more than 48 h (for full-term infant).
Statistical analysis
Outcome data were obtained from maternity databases as well as from detailed review of the patient's hospital notes. Categorical data are presented as number and percentage and continuous data as median and interquartile range. The chi-square test, or Fisher's exact test when appropriate, was used to compare categorical variables. The Mann-Whitney U-test was used for analysis of continuous data. P < 0.05 was deemed statistically significant. All statistical analyses were performed using IBM SPSS Statistics version 24 (IBM Corp., Armonk, NY, USA).
RESULTS
There were 166 women included in the analysis: 108 who had performed HBPM (with results recorded on the smartphone app in 29 cases and in their medical notes in 79 cases) and 58 control patients managed conventionally. Three (2.7%) of the women who were approached for HBPM declined, as they were not confident in using the technology. Two (1.8%) who commenced HBPM were excluded at their first review as it became clear they were non-compliant; they reverted to traditional care. Demographic characteristics and diagnosis at the beginning of blood-pressure monitoring and at the end of pregnancy are presented in Table 1 . There were significantly more women with chronic hypertension in the HBPM group compared with controls (49.1% vs 25.9%, P = 0.004). Significantly fewer patients developed PE in the HBPM group compared with the control group (20.4% vs 34.5%, P = 0.046). Across both HBPM and control groups, 20.6% of women with chronic hypertension and 32.1% of those with GH developed PE. The duration of outpatient monitoring was significantly longer in the HBPM group (8.9 vs 4.9 weeks, P = 0.004; Table 2 ). Patients in the HBPM group had significantly fewer visits per patient to the DAU (4 vs 6, P < 0.001). When also including other blood pressure-related visits to antenatal services (hypertension clinic, out-of-hours maternity triage, obstetric and midwifery antenatal clinic and general practitioner), the HBPM group had significantly fewer antenatal visits per patient (6.5 vs 8.0, P = 0.003). When calculated as the number of visits per patient per week, the HBPM group still had fewer visits compared with the control group (0.8 vs 1.6, P < 0.001). On subgroup analysis (Table 3) , women with chronic hypertension in the HBPM group had significantly fewer visits per patient to the DAU and fewer antenatal visits overall per patient per week compared with the control group. Women with GH also had significantly fewer visits per patient to the DAU compared with controls, but there was no difference in visits overall per patient per week. There was no significant difference between the HBPM group and controls, with respect to the days of blood pressure-related hospital admissions per patient in either the chronic hypertension or the GH subgroup.
There was no significant difference between the HBPM group and controls in the number of days of blood pressure-related hospital admissions or the number of days in HDU per patient between the two groups ( Table 2 ). There were also no significant differences between the groups in terms of gestational age at delivery, birth weight, admission to the neonatal unit, administration of steroids or magnesium sulfate, or maternal, fetal or neonatal adverse outcome (Table 4) .
DISCUSSION
Summary of study findings
Our results demonstrate that HBPM significantly reduced the number of DAU visits for blood pressure monitoring compared with traditional outpatient antenatal monitoring. HBPM was also associated with a significant reduction in antenatal outpatient visits overall per patient for hypertension-related reasons, and this reduction remained significant when taking into account differences in the duration of monitoring. The duration of monitoring was significantly longer in the HBPM group, which is likely to be due to the greater proportion of patients with chronic hypertension, who are likely to have started monitoring at an earlier gestational age. There were no significant differences in the number of days of hospital or HDU admission per person or any other markers of adverse maternal, fetal or neonatal outcome between the HBPM and the control group.
Interpretation of study findings and comparison with the literature
There is limited published literature on HBPM in hypertensive pregnant women. Our results demonstrate a lower number of visits to antenatal services by hypertensive pregnant women using HBPM, with no increase in adverse outcome for either mother or baby, compared with controls managed traditionally. Although our study was possibly underpowered to assess the adverse maternal, fetal and neonatal outcomes, our findings are supported by previous studies of home monitoring in women with GH [14] [15] [16] . In their pilot study, Lanssens et al.
14 compared retrospectively antenatal attendance and pregnancy outcome in 55 hypertensive women using remote monitoring with those in a hypertensive group managed by traditional means. Whilst they reported fewer hospital attendances in the remote-monitoring group, the difference was not significant on multivariate analysis. Importantly, their study populations differed, with the remote-monitoring group having fewer pre-eclamptic women, and the study utilized blood-pressure monitors that were not validated for use in pregnancy. Furthermore, the retrospective nature of their study increases the possibility of selection bias. Barton et al. 15, 16 reported similar maternal and perinatal outcomes, in their study of a large cohort of hypertensive pregnant women using HBPM. Although they also reported fewer days of hospital admission in the HBPM group, this difference was inevitable as the control group was a historical cohort managed as inpatients. The findings were also limited by a non-standardized management protocol defined by the patient's individual private physicians.
Study strengths and limitations
There were no significant differences between the HBPM and control groups with respect to maternal age, BMI, ethnicity, parity and smoking status, thereby reducing the risk of confounding for adverse outcome. Our study also benefits from robust data and outcome collection, in which all hospital notes as well as maternity databases were reviewed in order to gain detailed information about the numbers of visits and admissions, as well as pregnancy outcome. Furthermore, pregnant women in the HBPM group were reviewed by one specialist midwife, reducing variation in practice and related biases.
One of the limitations of our study is that the majority of patients in the HBPM group had chronic hypertension, whereas the control group had significantly more women with GH. This makes comparisons between the groups harder to interpret, as any differences may have been due to management of the underlying condition rather than HBPM itself. However, firstly, subgroup analysis demonstrated that, in HBPM patients compared with controls, there were still significantly fewer DAU and total outpatient visits when only the patients with chronic hypertension were analyzed, and significantly fewer DAU visits when only patients with GH were analyzed. Secondly, the control group was recruited retrospectively, meaning that selection bias cannot be excluded. Finally, our HBPM protocol was designed to comply with the organization and recommended practice of antenatal care in the UK, which may not be representative of antenatal care in other countries. This should be considered when applying the results to other populations.
Clinical and research implications
Despite the paucity of evidence regarding the use of HBPM in pregnancy, many professional bodies acknowledge its potential benefits and the need for further research 8, 17, 18 . This is one of few studies to compare HBPM with traditional monitoring in a hypertensive pregnant population. The finding of a reduction in number of hospital visits for hypertension-related reasons without an increase in maternal or fetal harm suggests that a large randomized trial is justified.
If women developed PE while using HBPM, they reverted to the traditional care pathway. Therefore, our findings cannot be applied to a PE population and the role of HBPM in PE remains unclear. Concerns over differences in home and clinic blood-pressure readings of PE patients using an automated device and mercury sphygmomanometry have been reported 19 , and, although validation studies for devices used in pregnancy often include PE patients, readings in this group may be less accurate 11, 20, 21 . Our study was not designed to compare the ability of HBPM with that of traditional monitoring to detect PE and this is an important question to be addressed in future research.
Ambulatory blood pressure monitoring in pregnancy has been shown to be effective in diagnosing white-coat hypertension and therefore reducing unnecessary intervention; HBPM is likely to offer a similar benefit 22, 23 . Conversely, it would be hoped that HBPM would allow for earlier detection of severe hypertension and PE by virtue of the patient's blood pressure being measured more frequently than if they were attending traditional outpatient monitoring. The fact that significantly fewer patients in the HBPM group progressed to PE may be explained by the fact that HBPM, as compared with conventional care, offers closer follow-up in women at risk for PE, allowing for better fine-tuning of antihypertensive therapy, with subsequent lower risk for progression to a more advanced and severe stage of the disease; however, the difference was small and should be interpreted with caution in view of the differences in the underlying diagnoses. Studies on ambulatory blood pressure monitoring have shown higher 24-h readings, as compared with routine blood-pressure measurements, in patients who subsequently develop PE or fetal growth restriction; however, refinement is required to enable these measures to be used as a prognostic tool [22] [23] [24] [25] [26] . HBPM is acceptable to patients and does not appear to increase anxiety 27, 28 . It requires fewer visits to hospital, which can save both time and money for patients. Already, many patients self-monitor their blood pressure in pregnancy without the advice of a healthcare professional and using a large variety of devices 10, 11 . It is therefore important to develop evidence-based protocols to ensure that this practice is performed safely. Finally, HBPM has the potential to offer cost savings and service improvements by reducing the number of lengthy visits required. This is important in both low-and high-income settings, all of which are under pressure to streamline services.
Conclusion
Our results suggest that using HBPM in hypertensive pregnancies has the potential to reduce the number of hospital visits required by patients without compromising safety. A larger prospective study is now warranted to explore further whether HBPM can make a difference in terms of requirements for antihypertensive treatment and early delivery for blood pressure-related reasons, and maternal and fetal adverse outcome.
